现在的位置: 首页研究点评, 进展交流>正文
[MEDSCAPE新闻]:献血者的年龄与性别不影响患者预后
2017年05月08日 研究点评, 进展交流 暂无评论

Blood Donor Age, Sex Do Not Affect Outcomes After All

Diana Swift

April 27, 2017

ecbw2023

Blood donor age and sex are not associated with recipient survival, and are therefore not relevant to donated blood allocation, according to a Scandinavian study of almost 1 million transfusions.

斯堪的纳维亚一项对将近100万名输血患者的研究显示,献血者年龄和性别与接受输血患者的生存率并不相关,因此,在分配血液时无需考虑上述因素。

The new findings, published online April 24 in JAMA Internal Medicine, contrast with those from a 2016 Canadian study. That study, which analyzed outcomes for more than 30,000 transfusion recipients, suggested blood from young or female donors was significantly associated with an increased risk for death among transfusion recipients compared with blood from older or male donors.

这些新的发现于2017年4月24日在线发表于JAMA Internal Medicine,其结果与2016年加拿大的研究结果并不一致。加拿大的研究对超过30,000名输血患者的预后进行了分析,结果提示,输注年轻或女性献血者的血液,患者死亡风险显著增加。

The Scandinavian researchers sought to replicate these findings, but after meticulously adjusting for the total number of transfusions, they found the association was eliminated.

斯堪的纳维亚的研究者希望重复上述研究,但对输血次数进行仔细校正后,他们发现上述相关性不再存在。

"Even among the patients who received multiple units of blood from very young or very old donors, absolute mortality differences compared with patients who received no such units of blood were consistently below 0.5%," write Gustaf Edgren, MD, PhD, from the Department of Medical Epidemiology and Biostatistics at the Karolinska Institutet in Stockholm, Sweden, and colleagues. They attribute the earlier findings of increased risk by donor age and sex not to biological effects but, rather, to the result of residual confounding from incomplete adjustment for the total number of transfusions.

“即使那些输注多个单位来自非常年轻或年长献血者的血液的患者,其绝对病死率差异也不超过0.5%,”瑞典斯德哥尔摩Karolinska研究院医学流行病和生物统计系的Gustaf Edgren医生及其同事写到。他们认为,早期研究发现,献血者年龄与性别伴随的风险增加并非源于生物学效应,而是由于未能对输血次数进行完全校正导致的残余混杂效应相关。

Using the same analytic methods as the Canadian group, Dr Edgren and colleagues studied Swedish (58.8%) and Danish recipients included in the SCANDAT2 database who were transfused at least once with red blood cells between 2003 and 2012. The median age of patients at first transfusion was 73 years, and 58.6% were women.

Edgren及其同事采用了与加拿大研究者相同的分析方法,对SCANDAT2数据库2003年至2012年间瑞典(58.8%)和丹麦至少输注一次红细胞的患者进行了研究。患者首次输血时中位年龄73岁,58.6%为女性。

Whereas crude analysis replicated some of the Canadian findings of age- and sex-linked risk, after careful adjustment for the total number of transfusions, neither donor age nor sex showed an association with patient mortality.

尽管初始分析复制了加拿大研究有关年龄和性别相关风险的部分结果,但对输血次数进行仔细校正后,献血者年龄或性别与患者病死率均没有相关性。

Specifically, the initial analysis showed a U-shaped relationship between donor age and recipient mortality, with the lowest occurrence in recipients of blood from the most common donor age group (40 - 49 years) and significant and increasing hazard ratios (HR) in recipients of blood from donors of the youngest and oldest (the least common) age groups. For example, with blood from donors younger than 20 years, the crude HR was 1.12 (95% confidence interval [CI], 1.10 - 1.14), and with that from donors aged 70 years and older, it was 1.25 (95% CI, 1.08 - 1.44).

值得注意的是,初始分析显示献血者年龄与输血者病死率之间呈U形关系,最常见的献血年龄组(40-49岁)对应的输血患者病死率最低,而最年轻及最年长献血者(最少的献血年龄组)对应的输血患者死亡风险比(HR)显著增加。例如,献血者年龄不足20岁时,未校正的HR为1.12(95% 可信区间 [CI], 1.10 - 1.14),献血者年龄 70 岁或更大时,HR为1.25 (95% CI, 1.08 - 1.44)。

Higher mortality risk also initially emerged in those receiving blood from female donors (HR, 1.07, 95% CI, 1.07 - 1.07).

输注来自女性献血者血液的患者死亡风险更高(HR, 1.07, 95% CI, 1.07 - 1.07).

Adjusting for the number of transfusions with a linear term, the researchers found the associations were attenuated but still present. Closer examination of the association between number of transfusions and survival, however, revealed a nonlinear pattern, and after additional statistical adjustment to account for this nonlinearity, donor age and sex were no longer associated with recipient mortality.

对输血次数进行线性校正后,研究者发现上述相关性虽然减弱但依旧存在。然而,对输血次数与生存率的相关性进行仔细检验发现,两者呈非线性相关性。针对这一非线性关系进行统计学校正后,献血者年龄与性别不再与输血者病死率相关。

The fully adjusted HR per transfusion from a donor younger than age 20 years fell to 0.98 (95% CI, 0.96 - 1.00), whereas the per unit HR for blood from a female donor fell to 0.99 (95% CI, 0.99 - 1.00).

进行完全校正后,每次输注来自年龄不足20岁的献血者的血液,HR下降到0.98 (95% CI, 0.96 - 1.00),而输注每个单位来自女性献血者的血液,HR 下降到 0.99 (95% CI, 0.99 - 1.00)。

"Assuming our approach is correct, these findings indicate that, with regard to recipient outcomes, neither of these donor characteristics need be considered when allocating red blood cell units for transfusion," Dr Edgren and coauthors write. " In addition, we believe these data reinforce the importance of extreme caution in assessing epidemiologic analyses in this field, given the tremendous clinical and logistical implications of false-positive findings."

“假设我们的方法是正确的,这些结果提示,当我们输血分配红细胞时,无需考虑献血者的特征,”Edgren医生及其同事写到。“另外,我们相信这些数据进一步强调,在评估这一领域流行病学分析时需要格外小心,因为假阳性结果可能产生很大的临床后果。”

Responding to the divergent findings, Michaël Chassé, MD, from Laval University in Quebec City, Quebec, who was lead author of the 2016 Canadian study, conceded that there may be residual confounding in his analysis. "Which statistical model is the best and represents the truth remains unclear and supports the need for prospective randomized confirmation," he told Medscape Medical News.

针对不同研究的矛盾结果,魁北克省魁北克市Laval大学的Michaël Chassé医生(2016年加拿大研究的首席作者)承认,其分析可能有残余混杂效应。“哪种统计模型最佳并反映事实,这仍不清楚,因此需要前瞻随机对照试验的验证。”他对Medscape医学新闻频道谈到。

"It is also possible that the included population and red blood cell components used are different in the different cohorts, so one sees an effect in one cohort but not in another." He points out that the Canadian cohort had a significantly higher proportion of donors younger than 20 years (5.9% vs 1.9%). "This provides more power to detect a difference in the youngest strata," he said.

“可能的其他原因包括不同队列研究中入选人群及输注的红细胞成分有所不同,因此,一项队列研究存在上述效应,而另一项研究则不存在”,他指出,加拿大队列中献血者年龄不足20岁的比例更高(5.9% vs. 1.9%)。“这使得检验最年轻献血者的把握度存在差异,”他谈到。

After two reanalyses, including one using the Scandinavian strategy, the Canadian group's conclusions remained largely unchanged, he added.

他补充到,在进行2次重新分析后(包括采用斯堪的纳维亚研究的分析方法),加拿大研究的结果并没有显著改变。

In an invited editorial, Nareg Roubinian, MD, MPHTM, from the Blood Systems Research Institute in San Francisco, California, and colleagues found the study results reassuring for current practice and the authors' explanation for their negative findings plausible. "They provide a convincing argument that differences in the statistical approach for controlling confounding by the total number of transfused components likely explained the divergent results of the 2 studies," Dr Roubinian and coauthors write.

在述评中,加州旧金山血液系统研究所的Nareg Roubinian医生及其同事认为,这一研究结果支持了现有临床常规,而且作者对于阴性结果的解释也是合理的。“他们提供了令人信服的解释,表明不同的统计分析对于输血次数的混杂效应进行校正,很可能解释了2项研究的矛盾结果,”Roubinian及其同事写到。

They suggest that the researchers could have controlled for confounding with the simpler approach of analyzing only patients who had received a single category of blood product (eg, only from female donors), but this method would exclude patients with mixed exposures and would discount the dose effect.

他们建议,研究者应当采用更简化的方法,仅仅分析那些输注单一血液制品(如仅输注女性献血者血液)的患者,这样可以校正混杂因素的影响,但这种方法会排除混合暴露的患者,而且可能影响量效关系。

According to the commentators, the disparate findings between the two studies underline the need for rigorous statistical methods in observational research on transfusion. "This conclusion also highlights the challenges and limitations of interpreting novel findings discovered by mining observational data rather than testing a priori hypotheses derived from biological mechanisms," they write.

根据他们的意见,两项研究的矛盾结果表明,在有关输血的观察性研究中,应当采取更为严格的统计学方法。“这一结论还表明,通过挖掘观察性研究数据得到新的结果,而非验证基于生物学机制的事先假设,这种策略所面临的挑战及局限性。”他们写到。

They also note that Dr Chassé and colleagues provided the Scandinavian team with methodological information that aided their analysis, "exemplifying the true spirit of scientific collaboration."

他们还指出,Chassé医生及其同事向斯堪的纳维亚研究团队提供了有助于分析的方法学支持,“这是科学协作精神的典型范例。”

Yet even with collaborations and improvements in statistical methods, Dr Roubinian and colleagues conclude that "rigorous attention is needed to avoid taking the wrong pathway. In the end, we are optimistic that future efforts to understand health outcomes associated with blood transfusion will benefit from these types of studies."

然而,尽管有统计方法的协作与改进,Roubininan及其同事仍得出结论,“需要格外小心避免采取错误的策略。最终,今后有关输血相关结局的认识一定会从这些研究中获益,我们对此表示乐观。”

This study was supported by the Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Society for Medical Research, the Karolinska Institutet, and the Danish Council for Independent Research. The authors and the commentators have disclosed no relevant financial relationships.

JAMA Intern Med. Published online April 24, 2017. Article abstract, Editorial extract

For more news, join us on Facebook and Twitter

给我留言

您必须 [ 登录 ] 才能发表留言!

×
腾讯微博